Recent Advances of Radionuclide-Based Molecular Imaging of Atherosclerosis

Kazuma, Soraya Megumi; Sultan, Deborah; Zhao, Yongfeng; Detering, Lisa; Meng, You; Luehmann, Hannah; Abdalla, Dulcinéia Saes Parra; Liu, Yongjian

doi:10.2174/1381612821666150915104529

Cited by 11 publications

(7 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These typically combine a targeting component, that ideally interacts specifically with the biochemical process being investigated, and an imaging component that can attach to the targeting component without affecting its interaction with the targeted biochemical process (5). In studies of atherosclerosis, unique molecular imaging agents have been developed for the assessment of a wide variety of FIGURE 1 | Molecular and Non-molecular thrombosis imaging strategies in atherosclerosis patients for assessing pathophysiological features related to early thrombosis at the molecular and cellular level (13), including ultrasound molecular imaging (6), magnetic resonance imaging (7), radionuclide imaging (14), optical imaging (15), intravascular ultrasound, optical coherence tomography, CT angiography (16), angioscopy and angiography (17).…”

Section: Non-molecular and Molecular Imaging Modalitiesmentioning

confidence: 99%

“… Molecular and Non-molecular thrombosis imaging strategies in atherosclerosis patients for assessing pathophysiological features related to early thrombosis at the molecular and cellular level ( 13 ), including ultrasound molecular imaging ( 6 ), magnetic resonance imaging ( 7 ), radionuclide imaging ( 14 ), optical imaging ( 15 ), intravascular ultrasound, optical coherence tomography, CT angiography ( 16 ), angioscopy and angiography ( 17 ). …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Molecular Imaging and Non-molecular Imaging of Atherosclerotic Plaque Thrombosis

Guo

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Thrombosis in the context of atherosclerosis typically results in life-threatening consequences, including acute coronary events and ischemic stroke. As such, early detection and treatment of thrombosis in atherosclerosis patients is essential. Clinical diagnosis of thrombosis in these patients is typically based upon a combination of imaging approaches. However, conventional imaging modalities primarily focus on assessing the anatomical structure and physiological function, severely constraining their ability to detect early thrombus formation or the processes underlying such pathology. Recently, however, novel molecular and non-molecular imaging strategies have been developed to assess thrombus composition and activity at the molecular and cellular levels more accurately. These approaches have been successfully used to markedly reduce rates of atherothrombotic events in patients suffering from acute coronary syndrome (ACS) by facilitating simultaneous diagnosis and personalized treatment of thrombosis. Moreover, these modalities allow monitoring of plaque condition for preventing plaque rupture and associated adverse cardiovascular events in such patients. Sustained developments in molecular and non-molecular imaging technologies have enabled the increasingly specific and sensitive diagnosis of atherothrombosis in animal studies and clinical settings, making these technologies invaluable to patients' health in the future. In the present review, we discuss current progress regarding the non-molecular and molecular imaging of thrombosis in different animal studies and atherosclerotic patients.

show abstract

Section: Non-molecular and Molecular Imaging Modalitiesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Molecular Imaging and Non-molecular Imaging of Atherosclerotic Plaque Thrombosis

Guo

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…38 Radiolabeled drug-delivering NPs have been used to establish drug uptake profiles and to predict treatment responses. 39 Radiolabeled NPs have also been used for molecular imaging of atherosclerosis 40 and many other diseases. There are several 99m Tc-labeled colloid-based SPECT imaging agents for cancer diagnosis that are currently clinically approved, either in the U.S. or EU, including Techneoll, Nanocoll, Hepatate, Nanocis, and Senti-Scint, primarily for lymphoscintigraphy of different cancer indications.…”

Section: Nanoparticles As Imaging Agentsmentioning

confidence: 99%

Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics

Ehlerding

Grodzinski

Cai³

et al. 2018

ACS Nano

132

View full text Add to dashboard Cite

The importance of medical imaging in the diagnosis and monitoring of cancer cannot be overstated. As personalized cancer treatments are gaining popularity, a need for more advanced imaging techniques has grown significantly. Nanoparticles are uniquely suited to fill this void, not only as imaging contrast agents but also as companion diagnostics. This review provides an overview of many ways nanoparticle imaging agents have contributed to cancer imaging, both preclinically and in the clinic, as well as charting future directions in companion diagnostics. We conclude that, while nanoparticle-based imaging agents are not without considerable scientific and developmental challenges, they enable enhanced imaging in nearly every modality, hold potential as in vivo companion diagnostics, and offer precise cancer treatment and maximize intervention efficacy.

show abstract

“…44 However, the primary disadvantage of optical imaging is its low depth penetration of only a few millimeters, as light is absorbed and scattered in tissue, limiting its potential application in human clinical research, as well as in small animals. 31 Another concern over fluorescence imaging is that the widely used fluorophores, such as cyanine dyes, 23 can suffer from photobleaching, limiting the ability to perform long-term tracking of cells.…”

Section: Imaging Modalities and Contrast Agents In Cell Trackingmentioning

confidence: 99%

Use of Nanoparticle Contrast Agents for Cell Tracking with Computed Tomography

Kim¹,

Chhour²,

Hsu³

et al. 2017

Bioconjugate Chem.

126

120

View full text Add to dashboard Cite

Efforts to develop novel cell-based therapies originated with the first bone marrow transplant on a leukemia patient in 1956. Preclinical and clinical examples of cell-based treatment strategies have shown promising results across many disciplines in medicine, with recent advances in immune cell therapies for cancer producing remarkable response rates, even in patients with multiple treatment failures. However, cell-based therapies suffer from inconsistent outcomes, motivating the search for tools that allow monitoring of cell delivery and behavior in vivo. Noninvasive cell imaging techniques, also known as cell tracking, have been developed to address this issue. These tools can allow real-time, quantitative, and long-term monitoring of transplanted cells in the recipient, providing insight on cell migration, distribution, viability, differentiation, and fate, all of which play crucial roles in treatment efficacy. Understanding these parameters allows the optimization of cell choice, delivery route, and dosage for therapy and advances cell-based therapy for specific clinical uses. To date, most cell tracking work has centered on imaging modalities such as MRI, radionuclide imaging, and optical imaging. However, X-ray computed tomography (CT) is an emerging method for cell tracking that has several strengths such as high spatial and temporal resolution, and excellent quantitative capabilities. The advantages of CT for cell tracking are enhanced by its wide availability and cost effectiveness, allowing CT to become one of the most popular clinical imaging modalities and a key asset in disease diagnosis. In this review, we will discuss recent advances in cell tracking methods using X-ray CT in various applications, in addition to predictions on how the field will progress.

show abstract

Recent Advances of Radionuclide-Based Molecular Imaging of Atherosclerosis

Cited by 11 publications

References 83 publications

Molecular Imaging and Non-molecular Imaging of Atherosclerotic Plaque Thrombosis

Molecular Imaging and Non-molecular Imaging of Atherosclerotic Plaque Thrombosis

Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics

Use of Nanoparticle Contrast Agents for Cell Tracking with Computed Tomography

Contact Info

Product

Resources

About